Achilles Therapeutics Plc Stock Price, News & Analysis

Achilles Therapeutics has joined the Northern Alliance for Advanced Therapies Treatment Centre consortium, funded by Innovate UK. This initiative aims to enhance the delivery of advanced therapy medicinal products, addressing challenges in clinical pathways from procurement to reimbursement. Achilles will leverage its expertise in supply chain management and cell therapy operations to identify gaps in current practices. The company is known for its precision T cell therapies targeting clonal neoantigens, currently undergoing Phase I/IIa trials for lung cancer and melanoma.

Achilles Therapeutics (NASDAQ: ACHL) will present an oral presentation and two posters at upcoming medical congresses. The 2021 ESGCT Congress will feature a presentation on October 22, focusing on a clonal neoantigen-reactive T cell therapy pipeline. Meanwhile, at the SITC 36th Annual Meeting on November 10-14, two posters will detail advancements in Clonal Neoantigen T cell (cNeT) therapies. Achilles specializes in precision T cell therapies targeting unique cancer markers. Upcoming details on abstracts and presentations will be released on specific dates.

Achilles Therapeutics plc (NASDAQ: ACHL) announced its participation in several investor conferences in September 2021. The presentations include the Wells Fargo Virtual Healthcare Conference on September 10, the H.C. Wainwright 23rd Annual Global Investment Conference starting September 13, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22. A webcast of the presentations will be available on the Achilles website.

Achilles Therapeutics has been granted US patent US 11,098,121 and European patent EP3347039B, covering a method to identify cancer patients likely to respond to checkpoint inhibitors by analyzing clonal neoantigens in their cancer cells. Research shows higher clonal neoantigens correlate with better responses to therapies. The patents enhance Achilles' intellectual property for precision T cell therapy targeting clonal neoantigens, utilizing its PELEUS bioinformatics platform. These advancements underscore the company's commitment to advancing cancer treatment.

Achilles Therapeutics (ACHL) reported significant progress in Q2 2021, presenting data at AACR and ASCO that demonstrates the ability to quantify active T cell components. The company closed a successful IPO, raising $175.5 million, enhancing its cash reserves to $299.3 million. R&D expenses rose to $10.8 million due to clinical trial activities. The net loss increased to $16.2 million, partly due to the higher share count post-IPO. Achilles is on track to share data from ten patients in the CHIRON and THETIS trials in Q4 2021, with plans to initiate higher dose patient enrollment soon.

Achilles Therapeutics plc (NASDAQ: ACHL) announced the enrollment of the first US patient in its CHIRON clinical trial for treating advanced non-small cell lung cancer (NSCLC) with precision T cell therapy. The trial, which has opened at 10 sites across the UK, EU, and US, aims to enroll up to 40 patients to assess the safety and efficacy of its clonal neoantigen T cell (cNeT) therapy. The CEO expressed optimism about the potential of their innovative approach targeting patient-specific neoantigens. Updates from 10 patients are expected in Q4 2021.

Achilles Therapeutics (NASDAQ: ACHL) presented a poster at the ASCO Annual Meeting 2021 regarding its ongoing phase I/IIa CHIRON trial, which evaluates clonal neoantigen T cells in advanced non-small cell lung cancer (NSCLC). The trial's primary objective is to assess the safety and tolerability of cNeT as a monotherapy and in combination with pembrolizumab, while secondary measures include clinical efficacy. Nearly 75% of NSCLC patients face metastatic disease, highlighting the necessity for innovative treatments like cNeT.

Achilles Therapeutics (NASDAQ: ACHL) reported key developments in its CHIRON and THETIS trials, receiving a go-ahead from the Independent Data Safety Monitoring Committee. The company completed an IPO, raising $175.5 million, with cash reserves expected to fund operations through late 2023. Initial clinical data from six patients indicated stable disease in four and tumor reduction in one. The operating expenses for Q1 2021 were $13.7 million, with a net loss of $13.8 million. Upcoming events include participation in the BofA Securities Healthcare Conference and presentation at the ASCO Annual Meeting.

Achilles Therapeutics plc (NASDAQ: ACHL) is part of a consortium awarded a €3 million ($3.6 million) grant from Horizon 2020, aimed at developing a tool to predict neoantigen immunogenicity. Led by UCL and including notable institutions like The Francis Crick Institute and the Weizmann Institute of Science, the project named DECOD-Ag will enhance cancer immunotherapy, aiming for personalized treatment strategies. Achilles will receive approximately €0.8 million ($1 million) from this funding, validating its expertise in neoantigen prediction algorithms.